Atomo Diagnostics: Admitted to All Ordinaries index
- Atomo Diagnostics (AT1) has had an impressive couple of months since it listing on the ASX in April
- The listing followed by an oversubscribed initial public offer, which raised $30 million
- Today, less than a full quarter of trading, Atomo was admitted to the S&P Dow Jones All Ordinaries Index
- During the quarter, Atomo received a number amount of orders for its rapid diagnostic test (RDT) devices due to COVID-19
- Due to this demand, the company is accelerating its manufacturing and is aiming to produce around 500,000 devices every month
- Despite the positive news, Atomo is down 7.69 per cent on the market today and is trading for 36 cents per share
